Efficacy of redifferentiation therapy in radioactive iodine refractory thyroid cancer: a systematic review and meta-analysis.
Emilia Zampella, Valeria Cantoni, Roberta Green et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed targeted redifferentiation therapy in patients with radioactive iodine (RAI)-refractory thyroid cancer. Across 15 studies involving 234 patients, the pooled rate of restored iodine uptake was 51% (95% CI: 30%-71%). In 11 studies reporting RECIST 1.1 outcomes, disease control was higher among redifferentiated than non-redifferentiated patients (93% [95% CI: 79%-100%] vs 54% [95% CI: 15%-91%]; P = 0.04). The pooled objective response rates were 28% and 8%, respectively, a difference that was not statistically significant (P = 0.33).
Key findings
- Successful redifferentiation occurred in a pooled 51% of patients (95% CI: 30%-71%).
- Pooled disease control was 93% (95% CI: 79%-100%) in redifferentiated patients versus 54% (95% CI: 15%-91%) in non-redifferentiated patients (P = 0.04).
- Pooled objective response was 28% (95% CI: 13%-44%) versus 8% (95% CI: 0%-44%), respectively (P = 0.33).
Why it matters
Restoring radioiodine avidity may provide a route to radioiodine treatment for some patients whose thyroid cancer is refractory to it. The higher pooled disease control among redifferentiated patients is encouraging, but the non-significant objective response comparison and lack of demonstrated long-term survival benefit mean these findings should be interpreted as preliminary.
What to keep in mind
The evidence came from 15 studies with small cohorts (3-33 patients); treatment response was assessed in 93 patients. The authors note that larger, standardized trials with extended follow-up are needed to establish prognostic differences and long-term survival benefit.